logo
Does the ‘cortisol cocktail' work for stress relief? An expert explains

Does the ‘cortisol cocktail' work for stress relief? An expert explains

CNN6 days ago
(CNN) — If you've spent time on TikTok or Instagram lately, chances are the 'cortisol cocktail' trending as the latest wellness hack has appeared in your feed. This colorful, nonalcoholic drink typically contains a mix of coconut water, citrus juice and certain salts. Also called an 'adrenal cocktail,' it has amassed millions of views, with influencers claiming it can lower stress hormones, boost energy and balance your body's adrenal function.
Almost half of Americans (49%) report frequent bouts of stress, and the number of people in the United States who are feeling stressed has been rising for the past two decades, according to a 2024 Gallup survey. In these uncertain times, a stress-relieving tonic feels just right as a soothing balm, but does it actually live up to the health claims?
What is cortisol and its relationship to stress? What nutrients are in these drinks and how are they purported to influence cortisol? Do they work? Who should be wary of trying this concoction?
To guide us through these questions, I spoke with CNN wellness expert Dr. Leana Wen. Wen is an emergency physician and adjunct associate professor at George Washington University. She previously was Baltimore's health commissioner.
CNN: What is cortisol and its relationship to stress?
Dr. Leana Wen: Cortisol is a steroid hormone produced by the adrenal glands, which are organs located above the kidneys. The hormone plays a vital role in many bodily functions, including regulating metabolism, blood sugar, blood pressure, sleep-wake cycles and immune responses. Cortisol is sometimes called the 'stress hormone' because its levels naturally rise when our bodies perceive a threat or stressful situation. This reaction is part of the body's 'fight-or-flight' response, helping people stay alert and react quickly when needed.
Those temporary increases in cortisol are a helpful evolutionary adaptation. Problems can arise when cortisol levels stay elevated for prolonged periods of time, which can happen when someone is under chronic stress. Persistently elevated cortisol is linked to problems such as poor sleep, anxiety, high blood pressure and even weakened immunity.
There are a number of medical conditions that can lead to abnormally high or low cortisol levels. Taking high doses of steroid medications or adrenal gland tumors are examples of conditions that can cause excess cortisol. Addison's disease, or primary adrenal insufficiency, is when the adrenal gland stops its usual function. This condition, and problems with the pituitary gland in the brain, could result in low cortisol levels.
CNN: What is in these 'cortisol cocktail' drinks, and how are they purported to influence cortisol?
Wen: Recipes vary, but they tend to have a combination of coconut water, juice (usually orange or some other citrus fruit) and some salts (commonly sea salt and/or magnesium). Sparkling water is often added to taste. Contrary to what the name may suggest, it typically does not contain any alcohol.
Each of the primary ingredients is supposed to play a role in supporting adrenal function and lowering stress. Coconut water is high in potassium, which helps maintain proper fluid and electrolyte balance. Citrus juice offers vitamin C, which plays a role in adrenal gland function. Salt and magnesium are supposed to replenish minerals depleted by stress. Moreover, some researchers believe that magnesium itself may help reduce feelings of anxiety or stress. Because of this, some versions of the cortisol cocktail include magnesium powder and/or cream of tartar, which has a high concentration of magnesium along with potassium and other salts.
CNN: Is there evidence that this drink actually lowers cortisol and reduces stress?
Wen: There is no scientific evidence that this drink has the effects it purports. While it's true that nutrients such as potassium, vitamin C and magnesium are important for healthy adrenal function, they are typically obtained in adequate amounts through a balanced diet. Bananas are the classic food high in potassium, but many others are packed with this mineral, too, such as raisins, apricots and tuna. Vitamin C can be found in citrus fruits, strawberries and peppers. And magnesium is also in many foods, including beans, peanut butter and leafy green vegetables.
True deficiencies in these nutrients can cause health problems, but such deficiencies are uncommon in otherwise healthy individuals. More importantly, there is no evidence that consuming extra amounts beyond what the body needs will provide additional benefits or that it will meaningfully lower cortisol levels.
CNN: What about the claim that the drink can treat a condition that influencers call 'adrenal fatigue'?
Wen: The claim that some influencers have promoted on social media is that there is a condition of 'adrenal fatigue' in which stress is overwhelming adrenal glands and people end up feeling tired, anxious and unable to cope with daily life. However, the symptoms could stem from a variety of causes, including poor sleep, mental health conditions, and undiagnosed diseases such as anemia, hypothyroidism and diabetes.
Importantly, there is no recognized medical diagnosis of adrenal fatigue. Outside of cases in which there are specific diseases causing adrenal insufficiency, there is no evidence that somehow the adrenal glands get overwhelmed and lose their ability to function. The symptoms often attributed to adrenal fatigue are real, but they are better explained by other, well‑studied causes. One risk I see is that people might rely on this so-called remedy instead of seeking medical evaluation for the real issues behind their fatigue or stress.
CNN: What about all the people on the internet who claim that they have had positive health outcomes as a result of this drink?
Wen: It may be that some individuals were not getting enough fluids or electrolytes before, and the additional hydration from the drink helped them feel more energized or clearheaded. There is also the placebo effect to consider: When people expect a certain treatment to work, they may genuinely feel better simply because they believe they are doing something beneficial for their health.
The ritual of making and drinking this drink could itself reinforce this sense of control and care, which can have real psychological benefits even if the drink's ingredients have no direct impact on cortisol.
CNN: Who should be wary of trying this so-called tonic?
Wen: People who should be cautious include individuals with chronic medical conditions such as kidney disease, heart disease and diabetes. Certain individuals with kidney disease need to be especially wary of food containing high amounts of potassium. Those with heart failure may be advised to restrict their fluid intake. The sugar in fruit juice may also be problematic for some people with diabetes.
Individuals interested in this drink should check with their doctor before adding this or any influencer-promoted wellness product to their diet. They should ask if any of their medications might interact with the drink's ingredients. And if they are experiencing symptoms — such as fatigue, anxiety or trouble sleeping — that prompted them to try this cocktail, they should discuss these concerns with their doctor to determine whether further evaluation is needed.
Get inspired by a weekly roundup on living well, made simple. Sign up for CNN's Life, But Better newsletter for information and tools designed to improve your well-being.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Strand Therapeutics Raises $153 Million Series B Financing to Further Advance Programmable mRNA Therapeutic Pipeline
Strand Therapeutics Raises $153 Million Series B Financing to Further Advance Programmable mRNA Therapeutic Pipeline

Yahoo

time17 minutes ago

  • Yahoo

Strand Therapeutics Raises $153 Million Series B Financing to Further Advance Programmable mRNA Therapeutic Pipeline

Funding will advance Strand's pipeline and mission to bring targeted, next-generation mRNA therapies to patients First-in-human solid tumor Phase 1 data from lead program, STX-001, was recently presented at 2025 ASCO Annual Meeting BOSTON, August 07, 2025--(BUSINESS WIRE)--Strand Therapeutics, a leader in next-generation mRNA-based therapeutics, today announced $153M Series B funding led by Kinnevik, with new investors Regeneron Ventures, ICONIQ, Amgen Ventures, Alderline Group (the family office of Alex Gorsky), JIC-VGI, LG Technology Ventures, and Gradiant Corporation, with continued participation from existing investors including FPV Ventures, Playground Global, Eli Lilly and Company, ANRI, and Potentum. To date, Strand has raised over $250M. As part of the financing, Ala Alenazi, Ph.D., of Kinnevik, will join the company's Board of Directors. The funding will advance Strand's pipeline, led by STX-001, a programmable mRNA therapy that expresses the cytokine interleukin-12 (IL-12) directly from the tumor microenvironment. The company recently announced promising initial Phase 1 clinical data for patients with advanced solid tumors at the 2025 ASCO annual meeting, noting multiple RECIST responses (including cases of complete response and complete metabolic response), multiple cases of prolonged disease stabilization, and a favorable safety profile in treatment-resistant patients. Earlier this year, Strand also presented preclinical data for STX-003, a world-first systemically administrable mRNA therapy with tumor targeting that is programmed to avoid off-target payload delivery (including liver avoidance), showing the first glimpse into the massive potential of their programmable mRNA genetic circuits. Data presented at the 2025 AACR and ASGCT annual meetings demonstrated the candidate's potential to target expression of IL-12 to tumors following systemic administration of the LNP-mRNA drug, creating an effective anti-tumor therapy that was well tolerated. IL-12 is a potent pro-inflammatory cytokine primarily produced by antigen-presenting cells such as macrophages and dendritic cells. IL-12 holds significant promise in cancer immunotherapy due to its robust immunostimulatory effects. STX-001 encodes IL-12 which Strand has designed so that it can reprogram the tumor microenvironment and stimulate a systemic anti-tumor immune response. Unlike traditional mRNA therapies, Strand's approach uses self-replicating mRNA, ensuring localized and durable therapeutic activity. "We believe programmable RNA is the next frontier in therapeutics, and Strand has built the leading platform to unlock it," said Christian Scherrer, Senior Investment Director and Head of Health and Bio at Kinnevik. "Their early clinical data is outstanding, and the systemic delivery capability has the potential to reshape how we treat disease, starting with cancer, with more disease targets on the horizon. We look forward to partnering with founders Jake and Tasuku and the entire team as they move into this next phase of growth." "With support from our investors, we're advancing our vision of developing safe, effective, and accessible therapies through programmable genetic medicines, especially for those patients with few treatment options," said Jake Becraft, PhD, CEO and Co-founder of Strand Therapeutics. "Our initial STX-001 Phase 1 data provides early and strong clinical validation of our platform's capabilities. We have observed systemic immune activation and anti-tumor responses, including responses in non-injected lesions, across multiple tumor types. Now is an exciting period of expansion for our existing clinical work, as well as the exciting breakthrough assets in our pipeline, all with the potential to transform the treatment of cancer and other serious diseases." Strand's proprietary platform for programmable and potent mRNA therapeutics is the first of its kind. Its therapies combine best-in-class engineered next-generation mRNA modalities, such as self-replicating mRNA and circular RNA, with genetically programmed logic circuits, allowing for precise, controlled therapeutic payload delivery directly into the cells/tissues themselves. The novel approach brings the potential to effectively treat cancer and other deadly chronic diseases through its targeted therapies that are scalable, accessible, and expand the treatment landscape for patients desperately in need. About STX-001 STX-001 is an investigational multi-mechanistic, synthetic self-replicating mRNA technology that expresses an IL-12 cytokine for an extended period of time, directly administered to tumors in order to promote immune modulation and antitumor activity. The company received IND clearance from the U.S. Food and Drug Administration (FDA) in December 2023 to initiate a Phase 1/2 clinical trial for STX-001, announced its first patient dosed just before the 2024 ASCO Annual Meeting, and presented the first data of the trial at the 2025 ASCO Annual Meeting. Additional details can be found at using identifier: NCT06249048. About Strand Therapeutics Strand Therapeutics is leading the next generation of programmable mRNA therapies: where synthetic biology meets programmable biology to unlock the full potential of gene regulation and delivery inside the body. Unlike traditional mRNA technologies, Strand's platform programs RNA to think, enabling logic-controlled expression, precision delivery, and unprecedented control over therapeutic outcomes. Born out of MIT and led by world-class synthetic biologists, Strand is building the infrastructure to create medicines that respond to disease signals in real-time. With its computationally-driven design engine, self-amplifying/circular RNA modalities, and mRNA-only genetic circuits, the company is pioneering a new therapeutic modality poised to disrupt immuno-oncology, cell therapy, autoimmune diseases, and beyond. Strand's lead pipeline program, STX-001, is already in the clinic showing unprecedented response rates in late stage "salvage" cancer patients, with multiple patients showing RECIST responses. Strand's modular platform opens a broad horizon of partnership and licensing opportunities. Strand isn't just another mRNA company: it's the operating system for the programmable medicines of tomorrow. Follow us on LinkedIn and on X at @strandtx. View source version on Contacts Media contacts:Karen Sharmaksharma@ Shannia Coleyscoley@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Natera Launches Fetal Focus™: A Noninvasive Prenatal Test for Inherited Conditions
Natera Launches Fetal Focus™: A Noninvasive Prenatal Test for Inherited Conditions

Yahoo

time17 minutes ago

  • Yahoo

Natera Launches Fetal Focus™: A Noninvasive Prenatal Test for Inherited Conditions

Launch supported by strong assay performance in first milestone readout of the landmark EXPAND clinical trial AUSTIN, Texas, August 07, 2025--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing and precision medicine, today announced the launch of Fetal Focus, a noninvasive prenatal test (NIPT) for inherited conditions. When a pregnant patient is identified as a carrier of a recessive single-gene condition, medical guidelines recommend partner testing in order to determine the risk for the baby to be affected by the condition1; however, in some cases the biological father is unavailable for testing. The Fetal Focus test was designed to address this unmet need. Now if a pregnant patient tests positive with Natera's Horizon™ carrier screen for one of the five most commonly tested genes, and if the father is unavailable for testing, Fetal Focus can screen the fetus directly for that gene by simply analyzing a sample of the mother's blood. Fetal Focus is validated for the analysis of five genes: CFTR (cystic fibrosis), SMN1 (spinal muscular atrophy), HBA1 and HBA2 (alpha-thalassemia), and HBB (beta-hemoglobinopathies, including sickle cell disease). The launch is supported by data from EXPAND, a large, prospective, blinded clinical trial. The study, which was initiated in 2023, has enrolled approximately 1,300 participants to date, reflecting a diverse, multi-ethnic population from leading academic medical centers and maternal fetal medicine clinics. EXPAND is designed to be the defining clinical trial in the category, with all outcomes, including both positive and negative results, confirmed by genetic truth using prenatal or postnatal diagnostic testing. In its first milestone readout (n=101) from EXPAND, the Fetal Focus test demonstrated 91% sensitivity and successfully identified 5/5 fetuses affected by homozygous variants.2,3 Homozygous cases, where the fetus inherits the same condition-causing variant from both parents, are especially challenging to detect. Fetal Focus uses Natera's proprietary LinkedSNP™ technology to improve detection of these cases across diverse populations. "Having access to a noninvasive option like Fetal Focus can provide critical information to support decision-making during pregnancy, especially in situations where partner testing isn't possible," said John Williams, M.D., chief principal investigator for EXPAND and director of reproductive genetics at Cedars-Sinai. "Fetal Focus adds another important offering within our comprehensive reproductive health portfolio – furthering our commitment to launching products that address clinical gaps in care and are supported by rigorous clinical validation," said Sheetal Parmar, M.S., CGC, senior vice president of medical affairs for women's health at Natera. "The EXPAND study has been underway for several years, and we're pleased to release this first milestone readout." References ACOG Committee Opinion #690, Mar 2017. Internal data on file. In EXPAND, the study participants and investigators are blinded to the Fetal Focus™ test results. EXpanding Prenatal Cell Free DNA Screening Across MoNogenic Disorders (EXPAND). Accessed July 2025. About Natera Natera™ is a global leader in cell-free DNA and genetic testing, dedicated to oncology, women's health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera's tests are supported by more than 300 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California. For more information, visit Forward-Looking Statements All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera's plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy and performance of our tests, or of the benefits of our tests and product offerings to patients, providers and payers. Additional risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera's recent filings on Forms 10-K and 10-Q and in other filings Natera makes with the SEC from time to time. These documents are available at and View source version on Contacts Investor Relations: Mike Brophy, CFO, Natera, Inc., investor@ Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., pr@ Sign in to access your portfolio

Celcuity Inc. Schedules Release of Second Quarter 2025 Financial Results and Webcast/Conference Call
Celcuity Inc. Schedules Release of Second Quarter 2025 Financial Results and Webcast/Conference Call

Yahoo

time17 minutes ago

  • Yahoo

Celcuity Inc. Schedules Release of Second Quarter 2025 Financial Results and Webcast/Conference Call

MINNEAPOLIS, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the second quarter 2025 after the market closes on Thursday, August 14, 2025. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. Webcast and Conference Call InformationTo participate in the teleconference, domestic callers should dial 1-800-717-1738 and international callers should dial 1-646-307-1865. A live webcast presentation can also be accessed using this weblink: A replay of the webcast will be available on the Celcuity website following the live event. About Celcuity Celcuity is a clinical-stage biotechnology company pursuing development of targeted therapies for treatment of multiple solid tumor indications. The company's lead therapeutic candidate is gedatolisib, a potent, pan-PI3K and mTORC1/2 inhibitor that comprehensively blockades the PAM pathway. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3Kα, AKT, or mTORC1 alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients. A Phase 1/2 clinical trial, CELC-G-201, evaluating gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer, is ongoing. A Phase 3 clinical trial, VIKTORIA-2, evaluating gedatolisib plus a CDK4/6 inhibitor and fulvestrant as first-line treatment for patients with HR+/HER2- advanced breast cancer is currently enrolling patients. More detailed information about Celcuity's active clinical trials can be found at Celcuity is headquartered in Minneapolis. Further information about Celcuity can be found at Follow us on LinkedIn and X. View source version of release on Contacts: Celcuity Inc. Brian Sullivan, bsullivan@ Vicky Hahne, vhahne@ (763) 392-0123 ICR HealthcarePatti Bank, (415) 513-1284Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store